In the present study, expression of mesenchymal marker vimentin was more frequent in early recurrence than in late recurrence cancers (P <0.001), and E-cadherin expression was lost in 112 (45.2%) of 248 early recurrence cancers, but only 35 late recurrence (22.7%) cancers showed loss of E-cadherin expression (P <0.001). Here, CDH1 is linked to cancer.